133 related articles for article (PubMed ID: 8874213)
1. CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease.
Robertson KD; Manns A; Swinnen LJ; Zong JC; Gulley ML; Ambinder RF
Blood; 1996 Oct; 88(8):3129-36. PubMed ID: 8874213
[TBL] [Abstract][Full Text] [Related]
2. Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature.
Kelly GL; Stylianou J; Rasaiyaah J; Wei W; Thomas W; Croom-Carter D; Kohler C; Spang R; Woodman C; Kellam P; Rickinson AB; Bell AI
J Virol; 2013 Mar; 87(5):2882-94. PubMed ID: 23269792
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic specifications of host chromosome docking sites for latent Epstein-Barr virus.
Kim KD; Tanizawa H; De Leo A; Vladimirova O; Kossenkov A; Lu F; Showe LC; Noma KI; Lieberman PM
Nat Commun; 2020 Feb; 11(1):877. PubMed ID: 32054837
[TBL] [Abstract][Full Text] [Related]
4. Epstein-barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt's lymphoma reflect virus strains prevalent in different geographic areas.
Habeshaw G; Yao QY; Bell AI; Morton D; Rickinson AB
J Virol; 1999 Feb; 73(2):965-75. PubMed ID: 9882297
[TBL] [Abstract][Full Text] [Related]
5. The importance of epigenetic alterations in the development of epstein-barr virus-related lymphomas.
Takacs M; Segesdi J; Banati F; Koroknai A; Wolf H; Niller HH; Minarovits J
Mediterr J Hematol Infect Dis; 2009 Nov; 1(2):e2009012. PubMed ID: 21416002
[TBL] [Abstract][Full Text] [Related]
6. Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma.
Cerimele F; Battle T; Lynch R; Frank DA; Murad E; Cohen C; Macaron N; Sixbey J; Smith K; Watnick RS; Eliopoulos A; Shehata B; Arbiser JL
Proc Natl Acad Sci U S A; 2005 Jan; 102(1):175-9. PubMed ID: 15611471
[TBL] [Abstract][Full Text] [Related]
7. 4C Analysis of EBV-Host DNA Interactome.
Kim KD; Lieberman PM
Methods Mol Biol; 2023; 2610():99-107. PubMed ID: 36534285
[TBL] [Abstract][Full Text] [Related]
8. Hodgkin's disease and the Epstein-Barr virus.
Flavell KJ; Murray PG
Mol Pathol; 2000 Oct; 53(5):262-9. PubMed ID: 11091850
[TBL] [Abstract][Full Text] [Related]
9. Unexpected patterns of Epstein-Barr virus transcription revealed by a high throughput PCR array for absolute quantification of viral mRNA.
Tierney RJ; Shannon-Lowe CD; Fitzsimmons L; Bell AI; Rowe M
Virology; 2015 Jan; 474():117-30. PubMed ID: 25463610
[TBL] [Abstract][Full Text] [Related]
10. Regulation of the EBNA1 Epstein-Barr virus protein by serine phosphorylation and arginine methylation.
Shire K; Kapoor P; Jiang K; Hing MN; Sivachandran N; Nguyen T; Frappier L
J Virol; 2006 Jun; 80(11):5261-72. PubMed ID: 16699006
[TBL] [Abstract][Full Text] [Related]
11. EBV and Apoptosis: The Viral Master Regulator of Cell Fate?
Fitzsimmons L; Kelly GL
Viruses; 2017 Nov; 9(11):. PubMed ID: 29137176
[TBL] [Abstract][Full Text] [Related]
12. Rheumatoid factors induce signaling from B cells, leading to Epstein-Barr virus and B-cell activation.
Yang L; Hakoda M; Iwabuchi K; Takeda T; Koike T; Kamatani N; Takada K
J Virol; 2004 Sep; 78(18):9918-23. PubMed ID: 15331725
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.
Niedobitek G
Mol Pathol; 2000 Oct; 53(5):248-54. PubMed ID: 11091848
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for Epstein Barr virus-associated cancers: a systematic review, critical appraisal, and mapping of the epidemiological evidence.
Bakkalci D; Jia Y; Winter JR; Lewis JE; Taylor GS; Stagg HR
J Glob Health; 2020 Jun; 10(1):010405. PubMed ID: 32257153
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) Enhances ATP Production in B Cell Tumors through mTOR and HIF-1α.
Incrocci R; Monroy Del Toro R; Devitt G; Salimian M; Braich K; Swanson-Mungerson M
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612754
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of epstein-barr virus DNA load in peripheral blood by quantitative competitive PCR.
Stevens SJ; Vervoort MB; van den Brule AJ; Meenhorst PL; Meijer CJ; Middeldorp JM
J Clin Microbiol; 1999 Sep; 37(9):2852-7. PubMed ID: 10449464
[TBL] [Abstract][Full Text] [Related]
17. MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs.
Wood CD; Veenstra H; Khasnis S; Gunnell A; Webb HM; Shannon-Lowe C; Andrews S; Osborne CS; West MJ
Elife; 2016 Aug; 5():. PubMed ID: 27490482
[TBL] [Abstract][Full Text] [Related]
18. Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients.
Babcock GJ; Decker LL; Freeman RB; Thorley-Lawson DA
J Exp Med; 1999 Aug; 190(4):567-76. PubMed ID: 10449527
[TBL] [Abstract][Full Text] [Related]
19. HIV infection and lymphoma.
Grogg KL; Miller RF; Dogan A
J Clin Pathol; 2007 Dec; 60(12):1365-72. PubMed ID: 18042692
[TBL] [Abstract][Full Text] [Related]
20. A gene panel, including LRP12, is frequently hypermethylated in major types of B-cell lymphoma.
Bethge N; Honne H; Andresen K; Hilden V; Trøen G; Liestøl K; Holte H; Delabie J; Lind GE; Smeland EB
PLoS One; 2014; 9(9):e104249. PubMed ID: 25226156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
